ADOCP logo

Adocia BATS-CHIXE:ADOCP Stock Report

Last Price

€7.82

Market Cap

€145.0m

7D

0%

1Y

133.4%

Updated

03 Feb, 2024

Data

Company Financials +

ADOCP Stock Overview

A clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. More details

ADOCP fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Adocia SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for Adocia
Historical stock prices
Current Share Price€7.82
52 Week High€10.16
52 Week Low€7.82
Beta0.83
1 Month Change0%
3 Month Changen/a
1 Year Change133.43%
3 Year Change-5.33%
5 Year Change-43.90%
Change since IPO22.38%

Recent News & Updates

Recent updates

Shareholder Returns

ADOCPGB BiotechsGB Market
7D0%-3.5%0.3%
1Y133.4%-23.5%6.6%

Return vs Industry: ADOCP exceeded the UK Biotechs industry which returned -26.7% over the past year.

Return vs Market: ADOCP exceeded the UK Market which returned -6.5% over the past year.

Price Volatility

Is ADOCP's price volatile compared to industry and market?
ADOCP volatility
ADOCP Average Weekly Movementn/a
Biotechs Industry Average Movement9.6%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.6%

Stable Share Price: ADOCP has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ADOCP's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200597Olivier Soulawww.adocia.com

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide.

Adocia SA Fundamentals Summary

How do Adocia's earnings and revenue compare to its market cap?
ADOCP fundamental statistics
Market cap€145.02m
Earnings (TTM)-€20.54m
Revenue (TTM)€10.84m

13.4x

P/S Ratio

-7.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ADOCP income statement (TTM)
Revenue€10.84m
Cost of Revenue€25.30m
Gross Profit-€14.46m
Other Expenses€6.09m
Earnings-€20.54m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Feb 27, 2024

Earnings per share (EPS)-1.46
Gross Margin-133.32%
Net Profit Margin-189.46%
Debt/Equity Ratio-119.7%

How did ADOCP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/02/03 02:01
End of Day Share Price 2023/11/06 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adocia SA is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric Le BerrigaudBryan Garnier & Co
Peter WelfordJefferies LLC
Seamus FernandezLeerink Partners LLC